Analysts at Leerink Partnrs lifted their FY2026 earnings estimates for Travere Therapeutics in a research report issued to ...

Investment analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on GH stock, giving a Buy rating yesterday.Invest with Confidence: ...

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on REPL stock, giving a Buy rating yesterday.Invest with ...

Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, ...

Schrodinger Inc (SDGR) stock saw a modest uptick, ending the day at $24.34 which represents a slight increase of $3.01 or 14.11% from the prior close of $21.33. The stock opened at $21.52 and touched ...

Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.49 which represents a slight increase of $0.61 or 8.87% from the prior close of $6.88. The stock opened at $7.17 ...

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering.

Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap ...